In therapeutic peptide API manufacturing, Fmoc-Gly-OH is managed as a structural raw material rather than a commodity reagent. The compound is received as Fmoc-glycine (CAS 29022-11-5, molecular formula C₁₇H₁₅NO₄, molecular weight 297.31 g/mol) and is incorporated into the growing peptide chain during solid-phase peptide synthesis. Compliance controls governing its use in this sector derive from ICH Q7 Section 7.2 for incoming material qualification, ICH Q3C for residual solvent limits in DMF and dichloromethane, and 21 CFR 210/211 when the resulting peptide API enters finished drug product manufacturing. For production-scale SPPS, Fmoc-Gly-OH is typically charged at 2.5–4.0 molar equivalents relative to the resin substitution. On aminomethyl or TentaGel supports loaded at 0.4–0.6 mmol/g, a 0.3 mol/L DMF solution of Fmoc-Gly-OH activated with DIC/Oxyma is delivered at 30–35 °C for 45–90 min. The downstream production process comprises repeated cycles of Fmoc removal with 20% piperidine in DMF, UV-based Fmoc-piperidine adduct monitoring at 301 nm, coupling under inert gas, and final cleavage with TFA/triisopropylsilane/water (95:2.5:2.5 v/v/v). After isolation by precipitation in cold MTBE, the crude peptide is purified by preparative RP-HPLC and lyophilized. Terminal product types in this application are therapeutic peptide APIs in which glycine occupies defined sequence positions. Bivalirudin, a bivalent thrombin inhibitor containing multiple glycine residues, is an example of a commercial peptide whose SPPS route uses Fmoc-Gly-OH as the glycine source. Production-scale experience shows that moisture ingress into the Fmoc-Gly-OH feed solution causes intermittent low coupling yields and forces double coupling; incoming water content determined by Karl Fischer titration is therefore routinely specified below 0.2% before large-scale campaigns.

Why does Fmoc-Glycine purity affect coupling efficiency in automated discovery-scale SPPS?

A CRO or CDMO producing custom peptide libraries for early-stage drug discovery operates under ISO 9001:2015 for non-GMP services, with optional ICH Q11 development guidance when a peptide candidate transitions into API development. At this scale, Fmoc-Gly-OH is charged at 2.5–5.0 molar equivalents relative to resin loading of 0.2–0.5 mmol/g, dissolved in DMF at 0.2 mol/L, and activated with HBTU/DIPEA or HATU/DIPEA in automated single-shot or parallel synthesizers. Microwave-assisted SPPS equipment operating at 50–75 °C shortens glycine coupling to 2–5 min; because glycine lacks a chiral center, racemization during activation is not the controlling failure mode. Instead, incomplete coupling is detected by Kaiser test or UV Fmoc release data and is most often traced to residual moisture in the solvent or to aged reagent batches with reduced Fmoc content. The downstream process includes Fmoc deprotection, sequential amino acid elongation, global deprotection and cleavage with TFA/triisopropylsilane/water, precipitation in cold diethyl ether, and parallel preparative HPLC purification. Terminal products include custom linear peptides, alanine-scanning peptide series, SAR-focused peptide libraries, and peptide substrates for enzyme activity assays. A standard incoming release panel for this sector includes appearance, HPLC purity ≥99.0%, TLC identity, and water content ≤0.2%. Because Fmoc-Gly-OH is achiral, specific rotation is not applicable; the central QC risk is the presence of Fmoc-related impurities derived from incomplete protection or residual solvent from crystallization.

Cosmetic-grade peptide synthesis using Fmoc-Gly-OH is governed by Regulation (EC) No 1223/2009, Annex I safety assessment, and by ISO 22716:2007 for cosmetics GMP, rather than by pharmaceutical GMP. The main commercial peptide in this sector for which Fmoc-Glycine serves as the N-terminal glycine input is copper tripeptide-1 (GHK-Cu), a histidine-containing tripeptide used in anti-aging and skin-repair formulations. For solid-phase assembly on Wang resin or 2-chlorotrityl resin at 0.5–1.0 mmol/g, Fmoc-Gly-OH is added in 3.0–4.0 molar equivalents with DIC/HOBt activation in DMF, producing a 0.25 mol/L coupling solution. The downstream process is conventional Fmoc SPPS: 20% piperidine deprotection, washing with DMF and isopropanol, TFA-mediated cleavage with a scavenger cocktail, precipitation in cold MTBE, purification by preparative RP-HPLC, and copper complexation after isolation of the glycyl-histidyl-lysine peptide. Terminal finished product types include copper tripeptide-1 powder, liquid anti-aging serums, eye contour formulations, and scalp treatment concentrates containing the peptide at product-specific low inclusion levels. One operational boundary in this sector is stricter control of residual solvent and elemental impurities in the peptide used for leave-on cosmetics. Fmoc-Glycine batches used for cosmetic peptide synthesis should be selected with residual piperidine and DMF levels consistent with downstream purification capacity, and oligomerized Fmoc-glycine by-products must be removed by HPLC because they can alter final peptide content specifications and chromatographic identity.

Peptide-drug conjugate linker assembly demands a chloride-controlled glycine synthon

In peptide-drug conjugate development, Fmoc-Gly-OH is used to install glycine residues into cleavable linker sequences rather than as a pharmacophore element. A glycine-glycine or glycine-PEG motif may serve as a spacer between the targeting peptide and the conjugated payload. Clinical-grade peptide-drug conjugate programs operate under ICH Q7 materials management for the linker intermediate and ICH Q11 for starting-material designation when the linker becomes part of the drug substance. In solid-phase linker assembly on 2-chlorotrityl chloride resin, the loading step itself generates free chloride, and residual chloride in subsequent coupling steps can reduce activation efficiency. Therefore, incoming Fmoc-Gly-OH is specified with chloride ≤0.05% and is charged at 2.5–4.0 molar equivalents relative to resin loading. A typical linker assembly uses Fmoc-Gly-OH dissolved in dry DMF/DCM mixtures at 0.2 mol/L, activated with DIC/Oxyma at 0–10 °C for chloride-sensitive systems, and coupled for 60–120 min. After Fmoc deprotection, the free N-terminal glycine is extended with protected amino acids or PEG building blocks. The downstream process includes selective cleavage from the acid-labile resin without disturbing side-chain protecting groups, preparative HPLC of the protected intermediate, conjugation to a cytotoxic or imaging payload, and final lyophilization. Terminal product categories are preclinical or clinical peptide-drug conjugates, peptide-cytotoxin conjugates, peptide-dye conjugates for fluorescence-guided surgery research, and radiolabeled peptide precursors in which the glycine-containing linker defines the distance between targeting head and chelator. Published data for specific commercial peptide-drug conjugate structures containing Fmoc-Glycine-derived glycine linkers is limited because linker chemistry is usually proprietary; the operational principle is nevertheless consistent with standard SPPS linker assembly.

For peptide-based diagnostic reagents and vaccine epitope research, Fmoc-Glycine is procured under ISO 13485:2016-aligned supply agreements when the peptide will be incorporated into an IVD kit component, with raw material traceability maintained according to 21 CFR 820 quality system requirements at the diagnostic manufacturer. The addition ratio for diagnostic peptide synthesis is normally 3.0 molar equivalents of Fmoc-Gly-OH relative to resin substitution of 0.1–0.5 mmol/g, with HBTU/DIPEA activation in DMF at 0.2 mol/L. Lower resin loading is preferred to reduce aggregation during glycine-containing epitope assembly. The downstream process is a standard Fmoc SPPS route: automated peptide synthesizer assembly, Fmoc deprotection with 20% piperidine in DMF, TFA cleavage, precipitation in cold ether, preparative RP-HPLC to ≥95% purity, and identity confirmation by ESI-MS. For diagnostic applications, UV quantification of the Fmoc deprotection product at 301 nm is used as an in-process control for substitution and coupling yield, not merely as a qualitative check. Terminal products include microbial peptide antigens, MHC-binding tetramer peptides, viral peptide controls for immunoassays, and peptide-coupled ELISA plate reagents. The main operational limitation is that diagnostic peptide batches may have less rigorous residual solvent specifications than pharmaceutical APIs, so the supplier must state DMF, methanol, and acetate levels separately when the peptide is not purified under GMP conditions. If a peptide is used as a quantitative standard, peptide content determined by amino acid analysis is mandatory to avoid overstating the active glycyl-peptide concentration.

When glycine residues are incorporated at the C-terminus on 2-chlorotrityl resin, process monitoring targets DKP formation rather than racemization

Research groups preparing glycine-containing peptide amphiphiles and low-molecular-weight peptide scaffolds use Fmoc-Gly-OH as a solid-phase building block, not as a gelator by itself. Published data on Fmoc-glycine gelation is limited, whereas Fmoc-diphenylalanine and related aromatic Fmoc-dipeptides are the more established gelators. Input ratios for research biomaterials fall within 2.5–4.0 molar equivalents relative to resin substitution, usually on 2-chlorotrityl chloride resin at 0.3–0.7 mmol/g, with DIC/Oxyma activation at 0.2 mol/L. The downstream production process is SPPS followed by cleavage with dilute TFA for protected peptide segments or full cleavage with scavenger cocktails for final peptide amphiphiles, precipitation in diethyl ether, and purification by preparative HPLC. When Fmoc-Gly-OH is introduced as the C-terminal residue on 2-chlorotrityl resin and the next residue is coupled and deprotected, the free N-terminal amine of that second residue can attack the glycyl ester carbonyl to form a diketopiperazine, releasing the dipeptide from the resin and creating yield loss. This route-specific failure mode is monitored by C18 HPLC analysis of the resin slurry and by mass balance after the second coupling. Terminal product types are peptide hydrogels for cell culture research, fibrous peptide scaffolds, glycine-spacer peptide amphiphiles, and peptide-functionalized surfaces for academic biomaterials laboratories. Compliance in this segment is typically limited to ISO 9001:2015 raw material supply and research-use labeling; no pharmacopoeial monograph applies to Fmoc-Gly-OH itself. The main operational boundary is that diketopiperazine formation becomes severe when the deprotected dipeptidyl-resin is stored in polar aprotic solvents above 25 °C; in manual synthesis, the interval between second-residue Fmoc removal and the next processing step is therefore kept below 15–30 min. Published data for this specific configuration is limited to laboratory-scale reproducibility rather than commercial manufacturing.